Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$9.0 million","newsHeadline":"Aquestive Therapeutics Licenses Sympazan\u00ae (clobazam) Oral Film to Assertio Holdings, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"LGS Foundation","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, Cipla Enters into Exclusive Distribution Partnership to Expand Reach of CNS Portfolio in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan\u00ae Oral Film Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Clobazam

    Menu

    Clobazam

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sanofi

              Contact Supplier
              • Deals
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi

              Details:

              Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium.

              Lead Product(s): Clobazam

              Therapeutic Area: Psychiatry/Psychology Product Name: Frisium

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Pharmanovia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Divestment September 18, 2023

              Sanofi Company Banner

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Cipla

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sanofi, Cipla Enters into Exclusive Distribution Partnership to Expand Reach of CNS Portfolio in India

              Details:

              Under the partnership, Cipla will be responsible for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range, including Frisium (clobazam), a brand in the anti-epileptic medication category, in India.

              Lead Product(s): Clobazam

              Therapeutic Area: Neurology Product Name: Frisium

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Assertio Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

              Details:

              SYMPAZAN (clobazam) is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

              Lead Product(s): Clobazam

              Therapeutic Area: Neurology Product Name: Sympazan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: LGS Foundation

              Deal Size: $0.1 million Upfront Cash: Undisclosed

              Deal Type: Partnership January 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Assertio Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent

              Details:

              Sympazan® (clobazam), oral film developed with PharmFilm® technology, is a prescription medicine used to treat seizures associated with Lennox-Gastaut Syndrome in people 2 years of age or older. Clobazam positive allosteric modulator of GABA receptor.

              Lead Product(s): Clobazam

              Therapeutic Area: Neurology Product Name: Sympazan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aquestive Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

              Details:

              Under the terms of the definitive agreement, Aquestive exclusively licensed the product’s intellectual property to Assertio for an upfront payment. Aquestive also entered into a long-term supply agreement with Assertio for Sympazan (clobazam) oral film.

              Lead Product(s): Clobazam

              Therapeutic Area: Neurology Product Name: Sympazan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Assertio Therapeutics

              Deal Size: Undisclosed Upfront Cash: $9.0 million

              Deal Type: Licensing Agreement October 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY